Fri, Jul 25, 2014, 11:15 AM EDT - U.S. Markets close in 4 hrs 45 mins


% | $
Click the to save as a favorite.

Savient Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • nowmac nowmac Feb 10, 2000 8:18 PM Flag

    Anyone else receive...

    I have not received the Warburg paper work you refer to. Is it somthing dealing with BTGC?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Draxis Health Starts Phase III Fibrimage
      MISSISSAUGA, Ont. -- Draxis Health Inc. (DRAX)
      said its Draximage Inc. radiopharmaceutical subsidiary
      has started Phase III
      clinical trials in Canada
      for Fibrimage, a diagnostic tool for deep vein
      thrombosis, or DVT.
      In a news release, the drug company
      said the trial should involve 130 patients and be
      completed by the end of the year.
      DVTs are blood clots
      that form in the lower limbs and can lead to a
      pulmonary embolism, or a blockage of blood flow to the
      lungs, a
      condition that kills about 200,000 people a
      year in the U.S., it said.
      It said Fibrimage is
      based on Fibrin Binding Domain, a recombinant
      polypeptide developed by Bio-Technology General Corp.

      (BTGC) and licensed to Draximage on an exclusive,
      worldwide basis

0.00190.0000(0.00%)May 30 3:56 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.